首页 > 市场调查报告书 > 製药

再生医学细胞疗法

市场调查报告书

商品编码

2008164

过继性细胞疗法市场：按类型、应用、最终用户和地区划分

Adoptive Cell Therapy Market, By Type (CAR-T, TCR-T, NK, TIL), By Application (Lymphoma, Leukemia, Others), By End User (Hospitals, Cancer Treatment Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版日期: 2026年03月06日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3个工作天内

价格

简介目录

据估计，2026年过继性细胞疗法市场规模为124.5亿美元，预计2033年将达224亿美元。预计2026年至2033年，该市场将以12.1%的复合年增长率成长。

分析范围		分析详情
基准年	2025	市场规模（2026 年）	124.5亿美元
效能数据	2020-2024	预测期	2026-2033
预测期（2026-2033 年）复合年增长率	12.10%	预计金额（2033 年）	224亿美元

过继性细胞疗法（ACT）是一种免疫疗法，它将T细胞（一种免疫细胞）输注给患者，以帮助他们对抗癌症等疾病。过继性细胞疗法包括嵌合体抗原受体（CAR）T细胞、T细胞受体（TCR）T细胞、肿瘤浸润淋巴细胞（TIL）和自然杀手（NK）细胞。在过继性细胞疗法中，将实验室大量培养的免疫细胞输注到患者体内以攻击癌细胞。在某些情况下，会使用能够自然辨识黑色素瘤的免疫细胞；而在其他情况下，则会使用经过基因改造、能够辨识并杀死黑色素瘤细胞的免疫细胞。过继性细胞疗法又称为T细胞转移疗法或细胞免疫疗法。

市场动态

全球过继性细胞疗法市场主要企业正致力于采取产品发布、合作和资金筹措等成长策略，预计这些策略将在预测期内推动市场成长。例如，2021年1月，全球临床阶段生物製药公司Gracell Biotechnologies Inc.宣布，其FasTCAR负载的BCMA/CD19双标靶CAR-T细胞疗法「GC012F」已获得美国食品药物管理局（FDA）授予的孤儿药资格认定，用于治疗多发性固体癌与主要企业Glycostem Therapeutics BV宣布，双方已达成协议。 Zelluna Immunotherapy 与 Glycostem Therapeutics BV 的这项合作将专注于开发和生产用于治疗癌症患者的同种异体 TCR 诱导的 NK 细胞疗法 (TCR-NK)。

本报告的主要特点

本报告指出了各个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
此外，它还提供了有关市场驱动因素和限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
本节根据以下参数介绍全球过继性细胞疗法市场中主要企业的概况：公司概况、产品系列、主要亮点、财务表现和策略。
本报告中的见解将使负责人和企业经营团队能够就未来的产品发布、产品线更新、市场扩张和行销策略做出明智的决策。
《全球过继细胞疗法市场》报告面向该行业的众多相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过分析全球过继性细胞疗法市场中使用的各种策略矩阵来促进决策。

北美洲
- 我们
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
中东
- GCC
- 以色列
- 其他中东国家
非洲
- 北非
- 中非
- 南非

第八章竞争情势

热图分析
市占率分析
公司简介
- Novartis AG
- Gilead Sciences, Inc.
- Castle Creek Biosciences, Inc.
- Lineage Cell Therapeutics, Inc.
- Transgene SA
- Cellectis
- ImmunityBio, Inc.
- Sorrento Therapeutics
- bluebird bio, Inc.
- Arcellx
- Sana Biotechnology, Inc.
- Biodesix, Inc
- Laurus Labs

第九章

参考
分析方法
关于 Coherent Market Insights

简介目录

Product Code: CMI4957

Adoptive Cell Therapy Market is estimated to be valued at USD 12.45 Bn in 2026 and is expected to reach USD 22.4 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 12.45 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	12.10%	2033 Value Projection:	USD 22.4 Bn

Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases, such as cancer. Types of adoptive cell therapy include chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumor infiltrating lymphocytes (TILs), and natural killer (NK) cells. Adoptive cell therapy involve use of immune cells that are grown in the lab in large numbers followed by administering them to the body to fight cancer. Sometimes, immune cells that naturally recognize melanoma are used, while other times they are modified to make them recognize and kill the melanoma cells. Adoptive cell therapy is also called T-cell transfer therapy, and cellular immunotherapy.

Market Dynamics

Key players operating in the global adoptive cell therapy market are focusing on adoption of growth strategies such as product launch, collaboration, and fundraise which are expected to drive the market growth during the forecast period. For instance, in January 2021, Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma. Moreover, in November 2019, Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment of multiple solid cancers, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company announced that they have entered into a development, license and supply agreement. This collaboration between Zelluna Immunotherapy and Glycostem Therapeutics BV will focus on the development and manufacture of allogeneic TCR guided NK cell therapies (TCR-NK's) for the treatment of patients with cancer

Key features of the study

This report provides an in-depth analysis of the global adoptive cell therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global adoptive cell therapy market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global adoptive cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global adoptive cell therapy market

Market Segmentation

By Type
- CAR-T
- TCR-T
- NK
- TIL
By Application
- Lymphoma
- Leukemia
- Others
By End User
- Hospitals
- Cancer Treatment Centers
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players
- Novartis AG
- Gilead Sciences, Inc.
- Castle Creek Biosciences, Inc.
- Lineage Cell Therapeutics, Inc.
- Transgene SA
- Cellectis
- ImmunityBio, Inc.
- Sorrento Therapeutics, bluebird bio, Inc.
- Arcellx, Sana Biotechnology, Inc.
- Biodesix, Inc
- Laurus Labs

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Adoptive Cell Therapy Market, By Type, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026- 2033
- Segment Trends
CAR-T
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
TCR-T
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
NK
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
TIL
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

5. Adoptive Cell Therapy Market, By Application, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

6. Adoptive Cell Therapy Market, By End User, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)

7. Adoptive Cell Therapy Market, By Region, 2026 - 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Novartis AG
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Gilead Sciences, Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Castle Creek Biosciences, Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Lineage Cell Therapeutics, Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Transgene SA
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Cellectis
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- ImmunityBio, Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Sorrento Therapeutics
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- bluebird bio, Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Arcellx
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Sana Biotechnology, Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Biodesix, Inc
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Laurus Labs
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Analyst Views

9. Section

References
Research Methodology
About Us

02-2729-4219

+886-2-2729-4219

License/价格

过继性细胞疗法市场：按类型、应用、最终用户和地区划分

Adoptive Cell Therapy Market, By Type (CAR-T, TCR-T, NK, TIL), By Application (Lymphoma, Leukemia, Others), By End User (Hospitals, Cancer Treatment Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

市场动态